Clinical Trial

Liquid Phase Concentrated Growth Factor Versus Conventional Arthrocentesis in Temporomandibular Disc Displacement

Study acronym: LPCGF in TMDs
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 11, 2026 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to rigorously assess the effectiveness of LPCGF in the management of internal disc displacement in patients with TMD through a randomized clinical trial. By comparing LPCGF therapy with conventional arthrocentesis, this research looks to provide robust evidence on the efficacy, safety, and potential role of (LPCGF) as an alternative therapeutic choice for IDD.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-11; most recent amendment 2026-03-08.
Status change: Not Yet Recruiting → Recruiting 2026-03-08
Trial Details
NCT Number NCT07075276
Lead Sponsor Horus University
Conditions Temporomandibular Disorders (TMD), Internal Derangement of the Tempromandibular Joint, Anterior Disc Displacement
Enrollment 32 participants
Start Date 2025-10-01
Primary Completion 2026-05-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-11